News – LUMICKS

Blog posts

Deciphering the Dynamic Mechanisms of Thymine DNA Glycosylase (TDG) in DNA Repair

Explore our latest blog post on thymine DNA glycosylase (TDG), where we delve into groundbreaking research using single-molecule assays to understand TDG’s crucial role in DNA repair. Discover how these insights could lead to advanced therapeutic strategies.

Chenlu Yu5 December 2024

Blog posts

Shu Complex: A New Frontier in DNA Repair and Cancer Therapy

Explore the groundbreaking research on the Shu Complex and its role in enhancing RAD51-mediated DNA repair. Discover how this vital mechanism can be a new target in cancer therapy and the innovative methods used in DNA repair studies.

Chenlu Yu22 November 2024

Blog posts

Unlocking the Power of Memory-Like NK Cells using Cell Avidity: A New Frontier in Cancer Immunotherapy

This is a summary of: Arellano-Ballestero, H., Zubiak, A., Dally, C., Orchard, K., Alrubayyi, A., Charalambous, X., Michael, M., Torrance, R., Eales, T., Das, K., Tran, M. G. B., Sabry, M., Peppa, D., & Lowdell, M. W. (2024).Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy.Journal for…

Andrea Candelli18 November 2024

Blog posts

Revealing MeCP2 Mechanism: Single-Molecule Insights into Epigenetic Regulation in Neurodevelopmental Disorders

Explore the dynamic mechanism of MeCP2 in gene expression regulation, its complex interactions with DNA, and implications for Rett syndrome. This research brief uncovers groundbreaking research using single-molecule methods to understand MeCP2’s impact on disease pathology and potential therapeutic targets.

Chenlu Yu24 October 2024

Press releases

Dutch Life Science Tools LUMICKS secures €20 million from European Investment Bank to accelerate drug discovery for cancer

Amsterdam-based LUMICKS signs €20 million venture debt with EIB to accelerate the development and launch of its new product, designed to advance immunotherapy development for cancer research. LUMICKS’ next generation high-throughput cell avidity platform aims to transform the drug discovery process by replacing traditional screening methods, expediting development for life-saving…

Chenlu Yu10 October 2024

Blog posts

DNA Polymerase Undergoes Rapid Exchange and Retains Memory at Replication Forks

Explore groundbreaking research on DNA polymerase exchange dynamics using the innovative C-Trap technology. Learn how this study offers new insights into DNA replication, polymerase activity, and the dynamic nature of the replisome. Ideal for both scientists and biotechnology professionals.

Chenlu Yu28 August 2024

Blog posts

Key mechanism in Fanconi Anemia pathway discovered with the C-Trap

Explore groundbreaking research on the FANCD2-I complex, central to the Fanconi anemia pathway, and its newly discovered mechanism in DNA repair and replication fork protection. This deep dive details the latest insights from recent studies, elucidating the complex's role in genomic stability and potential implications for cancer therapy.

Chenlu Yu1 August 2024

Blog posts

Cell Avidity uncovers critical binding mechanism impairing T-cell potency in the Tumor Microenvironment

A key mechanism deployed by the TME is the upregulation of immune checkpoint molecules. The BTLA-HVEM interaction between CAR-T cells and tumor cells has emerged as a critical factor in T-cell inhibition and exhaustion. This article covers the excellent work of researchers at UPenn that deleted BTLA in CAR-T cells.…

niels1 August 2024

Blog posts

Cell Avidity screening deployed by T cell pioneers to accelerate the identification of functional TCRs

The TCR field continues to rely on a protracted preclinical selection process, which utilizes conventional assays such as affinity and peptide titrations that correlate poorly with T-cell functionality. Optimal TCR selection necessitates thorough preclinical characterization, prompting Carr et al., to focus on comprehensive cell-cell binding assessment to enhance preclinical decision-making.

niels25 June 2024

Blog posts

Cell avidity-tuning ensures safe CAR-T therapy for solid tumors

Dive into our latest article where we shine the spotlight on the groundbreaking work carried out at the Dana-Farber Cancer Institute at Harvard Medical School where researchers utilized cell avidity-tuning to ensure the safety of their CAR-T therapy for targeting solid tumors.

niels5 June 2024

Join our newsletter